Haisco(002653)2025-04-24 11:40Financial Performance - The company's revenue for Q1 2025 was ¥892,013,011.11, representing an increase of 18.60% compared to ¥752,133,790.48 in the same period last year[5] - Net profit attributable to shareholders decreased by 49.31% to ¥46,611,871.33 from ¥91,955,910.47 year-on-year[5] - The basic earnings per share decreased by 50.00% to ¥0.04 from ¥0.08 in the same period last year[5] - Net profit for the current period was ¥46,598,128.91, a decrease of 48.6% from ¥90,718,987.55 in the previous period[19] - The company reported a total comprehensive income of ¥45,120,546.41, a decrease of 58.7% from ¥109,002,088.55 in the prior period[20] Cash Flow - The net cash flow from operating activities fell by 68.95% to ¥18,322,063.44, down from ¥59,000,571.51 in the previous year[5] - Cash inflow from operating activities was ¥948,751,469.90, slightly up from ¥941,867,968.09 in the previous period[21] - Net cash flow from operating activities decreased to $18.32 million from $59.00 million, a decline of approximately 69%[22] - Cash outflow from operating activities totaled $930.43 million, an increase from $882.87 million, indicating a rise of approximately 5%[22] - The net increase in cash and cash equivalents for the period was $242.31 million, compared to $280.46 million, a decrease of about 13%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,924,743,150.00, a 1.86% increase from ¥6,798,434,381.96 at the end of the previous year[5] - The total liabilities rose to ¥2,810,853,904.53, an increase of 8.2% from ¥2,596,189,993.38 in the previous period[16] - Current liabilities decreased to ¥1,499,917,309.79 from ¥1,568,218,563.33, showing a reduction of approximately 4.4%[15] - The company reported a significant increase in other liabilities, which rose by 567.09% to ¥24,302,903.39, primarily due to an increase in endorsed but not yet due bills[8] - Deferred income tax liabilities increased to ¥7,530,628.42 from ¥3,773,117.52, marking a growth of 99.1%[16] Research and Development - R&D expenses increased by 71.40% to ¥143,143,400.62, reflecting the company's commitment to enhancing competitiveness[8] - Research and development expenses increased significantly to ¥143,143,400.62, compared to ¥83,511,881.18 in the prior period, reflecting a growth of 71.5%[19] - The company has ongoing investments in research and development, with development expenditures amounting to ¥1,153,837,569.97[15] Market Strategy - The company is exploring market expansion opportunities, particularly in the healthcare sector, to enhance its product offerings and services[12] - The company is focused on strategic partnerships and potential acquisitions to strengthen its market position and drive growth[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,072, with the largest shareholder holding 35.68% of the shares[10] Other Financial Metrics - The weighted average return on equity dropped to 1.13% from 2.17% year-on-year, a decline of 1.04%[5] - The company experienced a 261.82% increase in non-operating expenses, totaling ¥7,537,637.71, mainly due to increased charitable donations[8] - Total operating costs amounted to ¥831,936,291.64, up 20.5% from ¥690,694,619.76 in the prior period[18] - Total cash inflow from investment activities was $203.70 million, down from $260.54 million, representing a decrease of about 22%[22]